Video Library
To commemorate the tenth anniversary of AONN+, leadership takes a look back at 10 of the association’s most significant accomplishments.
Drs. Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges in biomarker testing—tissue stewardship and complexity of biomarker tests and results—and ways to overcome these challenges—improved communication among all members of the cancer care team and simplification of biomarker test results to focus on actionable biomarkers.
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of test results with clinical outcomes, and the development of companion diagnostics for certain immunotherapies.
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.
Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.
Drs. Goeffrey Oxnard and Lauren Ritterhouse review the best practices to improve efficiencies in biomarker testing, including effective communication among the healthcare team, the pathologist, and the patient, as well as expediting processing in the pathology laboratory.
Drs. Goeffrey Oxnard and Lauren Ritterhouse consider the advantages and disadvantages of liquid biopsies as an early screening tool for biomarker testing, and how to integrate various approaches into a biomarker testing paradigm.
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Drs. Roy Herbst and David Rimm discuss ways in which the time required to complete biomarker testing can be reduced, from obtaining and processing tissues, performing the testing, evaluating results, and reporting results to the cancer care team.
Drs. Roy Herbst and David Rimm review some of the problems associated with obtaining enough tissue to perform biomarker testing, the need to triage tissue to ensure that standard of care tests are completed, and the potential role of liquid biopsies
